Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

Executive Summary

In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors – and investors – ahead of ASCO.

You may also be interested in...



Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.

IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC

The lack of significant overall survival benefit in IMpower132 may be related to PD-L1 expression – though the dataset is incomplete – or the higher dose of chemo used in the trial.

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC123143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel